Viewing results 1 - 6 of 5
Scientists from Uzbekistan and Hungary are collaborating to develop new health supplements derived from sweet wormwood (Artemisia annua), a plant known for its medicinal properties. The research is being conducted by the Pharmaceutical Institute of Tashkent and Hungary’s Meditop Pharmaceutical Ltd. The project is based on the groundbreaking work of Chinese scientist Tu Youyou, who won the 2015 Nobel Prize in Physiology or Medicine for discovering artemisinin, a compound extracted from sweet wormwood that effectively treats malaria. The joint initiative aims to produce antiseptic and anti-inflammatory supplements in various forms, including capsules, ointments, hydrogels, mouthwashes, and ear drops. These products are classified as food supplements rather than medicines. Currently, researchers are testing the active compounds on animals to evaluate their effectiveness. While still in the early stages of development, with prototypes being tested, mass production is planned to take place in Uzbekistan using Hungarian pharmaceutical expertise. It remains uncertain whether all prototypes will reach large-scale production, but both sides express optimism about the project’s potential. This collaboration is part of a broader partnership between the two countries. In 2023, Hungarian Foreign Minister Péter Szijjártó and Uzbek Minister of Investment, Industry, and Trade Laziz Kudratov announced plans to establish a special industrial zone in Uzbekistan for Hungarian companies. Sweet wormwood has been used in traditional medicine for centuries, particularly in Chinese medicine, where it has been employed to treat fever and infections. In recent years, artemisinin has been investigated not only for malaria treatment but also for its potential applications in cancer therapy and respiratory health, including during the COVID-19 pandemic.
Kazakhstan’s Minister of Science and Higher Education, Sayasat Nurbek, has announced the development of a domestic anti-cancer drug currently undergoing clinical trials. According to Nurbek, Phase II clinical trials were completed in 2023, and the number of patients participating in the testing has since been significantly expanded. "At the moment, the drug is being tested on different types of cancer. Last year, trials were conducted exclusively on patients with colorectal cancer. By the end of 2024, we expect the drug to be officially registered and introduced to the market. Preliminary results indicate stable positive dynamics," the minister stated. He noted that patients in clinical trials have experienced remissions, with tumor sizes decreasing by an average of 30%. "By the end of the year, we plan to hold a conference to present the results. The Ministry of Health has been highly supportive, and we have optimized the registration process without violating regulations," Nurbek added. The official registration of the drug is expected to be finalized as soon as possible. Kazakhstan's development of its first domestically produced anti-cancer drug was first reported in January 2024. Later, Nurbek provided updates on the trial progress and expressed confidence in the drug’s effectiveness.
Kyrgyzstan has taken a significant step toward reducing its dependence on imported pharmaceuticals with the launch of domestic medicine production at the Aidan Pharma pharmaceutical plant. The facility has begun manufacturing its first batch of essential medications, including: Paracetamol (suspensions and tablets); Ibuprofen (suspensions); Acetylsalicylic acid (tablets); and Acyclovir (tablets). The plant has the capacity to produce up to 10,000 packages of each of these medicines per day, offering an important boost to the country’s pharmaceutical industry. In late 2023, Aidan Pharma began producing medical ethyl alcohol, which is now supplied to state hospitals and pharmacies. During a visit to the plant on January 10, Health Minister Alymkadyr Beishenaliev announced plans to expand the plant’s product range to 100 items by the end of this year. He also revealed that the company intends to begin exporting its products in the future. “The plant's products meet quality standards and have a low production cost, making them more affordable compared to imported medicines,” Beishenaliev noted. The Kyrgyz government has prioritized reducing the country’s reliance on imported medications. In December 2024, the Cabinet of Ministers approved an investment agreement for a Kyrgyz-Chinese pharmaceutical project led by Standard Pharm Group. This initiative will focus on packaging pharmaceuticals and constructing a new pharmaceutical plant in Kyrgyzstan. The project, which will be implemented in two stages over five years, is expected to attract over $41 million in investment. According to Minister of Economy and Commerce Bakyt Sydykov, the plant will manufacture a range of medicines, including: Nutritional infusions; Antibacterial, anti-inflammatory, and antipyretic medications; Analgesics; Hypoglycemic treatments; and Gastrointestinal drugs. Most of these medicines are included in Kyrgyzstan’s List of Vital Medicines, a critical inventory of essential pharmaceuticals that are currently not produced domestically. The development of Kyrgyzstan’s pharmaceutical industry marks a critical shift toward self-sufficiency in healthcare. By expanding domestic production, the government aims to make essential medications more accessible and affordable for its population while fostering economic growth through investment and exports.
On October 24, the Swiss pharmaceutical giant F. Hoffmann-La Roche Ltd., in partnership with Nobel Almaty Pharmaceutical Factory JSC, launched the production of innovative drugs in Almaty. The project followed an agreement between Roche, Kazakhstan’s SK-Pharmacy LLP, Nobel, and the Kazakh Research Institute of Oncology and Radiology, with the support of National Company Kazakh Invest. Under the agreement, Roche committed to establishing local production of three biotechnological drugs for the treatment of HER2-positive breast cancer, an aggressive form of the disease that affects up to 20% of breast cancer patients in Kazakhstan. At the opening ceremony, Kazakhstan's Minister of Health, Akmaral Alnazarova, said: "The localization [of production] of oncological drugs by a global leader like Roche is a huge step forward for our country. This project will provide patients access to advanced treatments and significantly contribute to developing Kazakhstan's healthcare infrastructure.” The transfer of Roche's advanced technologies and production capabilities to local partners will reduce healthcare system costs in Kazakhstan and significantly expand patient access to essential medicines. Around 5,000 new cases of breast cancer are registered in the country annually, with approximately 1,200 resulting in death. This project is expected to increase the number of patients receiving therapy to 1,335 by 2026. The project is part of Kazakhstan’s plan to increase the share of domestically produced medicines and medical devices to 50%.
Kyrgyzstan's Health Ministry has devised an initiative to legalize traditional folk medicine. A draft decree of the Cabinet of Ministers on the procedure for training specialists has now been submitted for public discussion. Proposed by Minister of Health Alymkadyr Beishenaliev, the initiative concerns the study of traditional healing methods such as phytotherapy, massage, acupuncture, apitherapy, and hippotherapy, conducted through specialist training programs. He has also mooted the establishment of a research institute or Academy of Traditional Kyrgyz Medicine offering courses in theoretical and practical skills taught by professionals in the field, alongside the foundation of a dissertation council for the defense of academic degrees in the discipline. Central to the project, is the introduction of a budget for traditional medicine specialists, such as acupuncturists and physiotherapists, in all medical institutions of the country. There are also plans to open a research institute to test the efficacy of medicinal plants and conduct clinical trials. In addition, the Cabinet of Ministers has proposed the implementation of medicinal herb plantations for the subsequent production of related medical drugs. It is worth noting that in both several former Soviet Union and countries worldwide, traditional medicine has been legalized and integrated into state healthcare systems. For example, Russia and Belarus practice traditional treatments, including phytotherapy, acupuncture, alongside modern medical procedures. Traditional Chinese medicine is widely practiced in China, Japan, and Korea, and Ayurveda and Yunani are actively being developed in India. The World Health Organization also supports the development of traditional medicine by helping countries develop recognized international standards.
